Hollis-Eden Pharmaceuticals to Webcast Investor Conference Presentations and Third Quarter 2008 Conference Call
15 Outubro 2008 - 8:00AM
Business Wire
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced
that it has scheduled the following investor conference
presentations and third quarter 2008 conference call to review its
clinical development programs and provide an update on operating
results: BIO Investor Forum 2008 in San Francisco on October 30,
2008, at 11:30 a.m. Pacific. Rodman and Renshaw Annual Global
Investment Conference in New York City on November 10, 2008, at
9:55 a.m. Eastern. A live webcast will be available from each of
these conferences, and may be accessed under �Event Calendar� on
the Investors section of Hollis-Eden�s website at
www.holliseden.com. The webcasts will be archived at the Company�s
website for 30 days. Richard Hollis, Chairman and CEO of
Hollis-Eden, will be delivering the presentations. Third Quarter
2008 Conference Call and Webcast November 6, 2008 at 2:00 p.m.
Eastern (11:00 a.m. Pacific). Hollis-Eden will release financial
results prior to the market opening that day. The conference call
can be accessed by dialing 800-901-5248 (domestic) or 617-786-4512
(international) and requesting the Hollis-Eden conference call. A
live webcast of the conference call will be available under �Event
Calendar� on the Investors section of Hollis-Eden�s website at
www.holliseden.com. The webcast will be archived at the Company�s
website for 30 days, and a replay of the call will be available by
phone for 24 hours beginning approximately one hour after the call
is completed, and can be accessed at 888-286-8010 (domestic) or
617-801-6888 (international), passcode 85690948. About Hollis-Eden
Pharmaceuticals, Inc. Hollis-Eden Pharmaceuticals, Inc. is a world
leader in the development of a proprietary class of adrenal steroid
hormones as novel pharmaceuticals for human health. Through its
Hormonal Signaling Technology Platform, Hollis-Eden is developing a
new series of small molecule compounds that are metabolites or
synthetic analogs of endogenous hormones derived by the adrenal
glands from the body�s most abundant circulating adrenal steroid.
These steroid hormones, designed to restore the biological activity
of cellular signaling pathways disrupted by disease and aging, have
been demonstrated in humans to possess several properties with
potential therapeutic benefit -- they regulate innate and adaptive
immunity, reduce nonproductive inflammation and stimulate cell
proliferation. The Company�s clinical drug development candidates
include TRIOLEX� (HE3286), a next-generation compound currently in
clinical trials for the treatment of type 2 diabetes ulcerative
colitis and rheumatoid arthritis, and APOPTONE� (HE3235), a
next-generation compound in a clinical trial for late-stage
prostate cancer. In addition to these clinical development
candidates, Hollis-Eden has an active research program that is
generating additional new clinical leads that are being further
evaluated in preclinical models of a number of different diseases.
For more information on Hollis-Eden, visit the Company's website at
www.holliseden.com. This press release contains forward-looking
statements within the meaning of the federal securities laws
concerning, among other things, the potential and prospects of the
Company's drug discovery program and its drug candidates. Any
statement included in this press release that are not a description
of historical facts are forward-looking statements that involve
risks, uncertainties, assumptions and other factors which, if they
do not materialize or prove correct, could cause the Company's
actual results to differ materially from historical results or
those expressed or implied by such forward-looking statements. Such
statements are subject to certain risks and uncertainties inherent
in the Company�s business, including, but not limited to: the
ability to complete preclinical and clinical trials successfully
and within specified timelines, if at all; the ability to obtain
regulatory approval for TRIOLEX (HE3286), APOPTONE (HE3235) or any
other investigational drug candidate; the Company's future capital
needs; the Company's ability to obtain additional funding; the
ability of the Company to protect its intellectual property rights
and to not infringe the intellectual property rights of others; the
development of competitive products by other companies; and other
risks detailed from time to time in the Company's filings with the
Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Except as required by law, the Company undertakes no
obligation to update or revise the information contained in this
press release as a result of new information, future events or
circumstances arising after the date of this press release.
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Hollis-Eden Pharmaceuticals (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Hollis-Eden Pharmaceuticals, Inc.